Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 37 - Drugs for immunological or allergic disorders
Patents for A61P 37 - Drugs for immunological or allergic disorders (117,141)
10/2000
10/12/2000DE19915862A1 Verwendung von molekulargewichtserweitertem Hirudin als Antikoagulans bei der extrakorporalen Nierenersatztherapie Use of molekulargewichtserweitertem hirudin as an anticoagulant in extracorporeal renal replacement therapy
10/12/2000DE19915365A1 Tetrahydropyridazin-Derivate Tetrahydropyridazine derivatives
10/12/2000CA2373717A1 Pyrrolidine modulators of chemokine receptor activity
10/12/2000CA2369446A1 Substituted azetidin-2-ones as cysteine protease inhibitors
10/12/2000CA2369238A1 Cell adhesion-inhibiting antiinflammatory and immune-suppressive compounds
10/12/2000CA2369071A1 Novel lipoic acid derivatives, their preparation, pharmaceutical use and pharmaceutical compositions cantaining them
10/12/2000CA2369005A1 Inhibitors of lfa-1 binding to icams and uses thereof
10/12/2000CA2368686A1 Substituted 1,4-dihydroindeno[1,2-c]pyrazoles as inhibitors of tyrosine kinase
10/12/2000CA2368240A1 N-(2-phenyl-4-amino-butyl)-1-naphthamides as neurokinin-1 receptor antagonists
10/12/2000CA2368225A1 Antigen-specific induction of peripheral immune tolerance
10/12/2000CA2367403A1 Dsp-9 dual-specificity map kinase phosphatase
10/12/2000CA2367378A1 Molecules of the immune system
10/12/2000CA2367143A1 Purine derivatives having phosphodiesterase iv inhibition activity
10/12/2000CA2367109A1 Dsp-4 dual-specificity map kinase phosphatase
10/12/2000CA2367104A1 Dsp-7 dual-specificity map kinase phosphatase
10/12/2000CA2367100A1 Transdermal drug delivery devices comprising a polyurethane drug reservoir
10/12/2000CA2366944A1 Pyrrolidine modulators of chemokine receptor activity
10/12/2000CA2366895A1 Immunomodulating polymers
10/12/2000CA2366264A1 Novel amide derivatives as inhibitors of matrix metalloproteinases, tnf-.alpha., and aggrecanase
10/12/2000CA2365834A1 Herbal compositions and uses for the treatment of allergic reactions
10/12/2000CA2365825A1 Caspase inhibitors for inhibiting blood cell proliferation and for treating autoimmune diseases
10/12/2000CA2365500A1 Association of no-synthase inhibitor(s) and metabolic antioxidant(s)
10/12/2000CA2365421A1 Vesicle associated proteins
10/11/2000EP1043333A1 NOVEL POLYPEPTIDES, cDNAS ENCODING THE SAME AND UTILIZATION THEREOF
10/11/2000EP1043317A1 Novel pyridazine derivatives and drugs containing the same as the active ingredient
10/11/2000EP1042674A1 148 human secreted proteins
10/11/2000EP1042495A1 Delivery of polypeptide-encoding plasmid dna into the cytosol of macrophages by attenuated suicide bacteria
10/11/2000EP1042456A1 Human nucleotide pyrophosphohydrolase-2
10/11/2000EP1042365A1 Compounds and methods for modulating occludin related tissue permeability
10/11/2000EP1042349A1 Using polyamide nucleic acid oligomers to engender a biological response
10/11/2000EP1042343A1 Vegi, an inhibitor of angiogenesis and tumor growth
10/11/2000EP1042317A1 New pharmaceutically active compounds
10/11/2000EP1042316A1 Indole derivatives useful a.o. for the treatment of osteoporosis
10/11/2000EP1042315A1 Cyclic imide-substituted pyridylalkane, alkene, and alkine carboxamides useful as cytostatic and immunosuppressive agents
10/11/2000EP1042307A1 Aminothiazole inhibitors of cyclin dependent kinases
10/11/2000EP1042300A1 Phthalazine derivatives phosphodiesterase 4 inhibitors
10/11/2000EP1042291A1 Aryl-substituted pyridylalkane, alkene, and alkine carboxamides useful as cytostatic and immunosuppressive agents
10/11/2000EP1042286A1 Gamma-glutamyl and beta-aspartyl containing immunomodulator compounds and methods therewith
10/11/2000EP1042280A2 Prodrugs of aspartyl protease inhibitors
10/11/2000EP1042001A1 Use of microparticles combined with submicron oil-in-water emulsions
10/11/2000EP1041994A1 Use of parasitic biological agents for prevention and control of autoimmune diseases
10/11/2000EP1041991A1 Method for inhibiting cyclooxygenase-2 and tumor necrosis factor alpha
10/11/2000EP1041990A1 Composition for treating respiratory and skin diseases, comprising at least one leukotriene antagonist and at least one antihistamine
10/11/2000EP1041982A1 INHIBITION OF p38 KINASE ACTIVITY USING SUBSTITUTED HETEROCYCLIC UREAS
10/11/2000EP1041896A2 Fat blend
10/11/2000EP0719328B1 Grb3-3 gene, variants and uses thereof
10/11/2000EP0710121B1 Method for treating multiple sclerosis
10/11/2000EP0650485B1 2,5-diaryl tetrahydro-thiophenes, -furans and analogs for the treatment of inflammatory and immune disorders
10/11/2000CN1269832A Kay-novel immune system protein
10/11/2000CN1269722A Method and composition for modulating responsiveness to corticosteroids
10/11/2000CN1269715A Method and composition for treating late allergic reactions and inflammation diseases
10/11/2000CN1057296C Morpholine and thiomorpholine tachykinin receptor antagonists and use
10/11/2000CN1057231C Modulation of AIDS virus-related events by double-stuanded RNAs
10/11/2000CN1057212C Oral liquor for body-building
10/10/2000US6130326 L-ribavirin. oh; anticarcinogenic/antitumor agents; viricides; fungicides; treatment of autoimmune diseases
10/10/2000US6130318 hIL-4 mutant proteins used as antagonists or partial agonists of human interleukin 4
10/10/2000US6130244 Product and method to reduce stress induced immune suppression
10/10/2000US6130233 Methods and compositions for treating allergic disorders and other disorders using metabolic derivatives of astemizole
10/10/2000US6130087 Methods for generating cytotoxic T cells in vitro
10/10/2000US6130066 Vectors having enhanced expression and methods of making and uses thereof
10/10/2000US6129921 Viral ribonucleocapsid as an immunological enhancer
10/10/2000US6129913 Recombinant IL-5 antagonists useful in treatment of IL-5 mediated disorders
10/10/2000CA2062969C Recombinantly produced human membrane cofactor protein (mcp)
10/10/2000CA2056421C Agent against autoimmune diseases
10/05/2000WO2000058513A1 49 human secreted proteins
10/05/2000WO2000058495A1 45 human secreted proteins
10/05/2000WO2000058494A1 50 human secreted proteins
10/05/2000WO2000058473A2 Nucleic acids including open reading frames encoding polypeptides; 'orfx'
10/05/2000WO2000058468A2 47 human secreted proteins
10/05/2000WO2000058467A1 50 human secreted proteins
10/05/2000WO2000058466A2 Protease resistant flint analogs
10/05/2000WO2000058463A1 Polynucleotide and deduced amino acid sequences from stromal cells
10/05/2000WO2000058453A2 Plants transformed with thioredoxin
10/05/2000WO2000058365A1 Specific binding proteins for treating canine allergy
10/05/2000WO2000058355A1 50 human secreted proteins
10/05/2000WO2000058350A1 49 human secreted proteins
10/05/2000WO2000058349A1 Peptide vaccine for canine allergy
10/05/2000WO2000058341A1 Hookworm platelet inhibitor
10/05/2000WO2000058340A2 50 human secreted proteins
10/05/2000WO2000058339A2 50 human secreted proteins
10/05/2000WO2000058336A1 50 human secreted proteins
10/05/2000WO2000058334A1 50 human secreted proteins
10/05/2000WO2000058318A1 Phosphate containing macrocyclic immunomodulators
10/05/2000WO2000058314A2 Sulfamate containing macrocyclic immunomodulators
10/05/2000WO2000058307A2 Aryl fused 2,4-disubstituted pyridines: nk3 receptor ligands
10/05/2000WO2000058305A1 Novel compounds
10/05/2000WO2000058295A2 Compounds and methods for treatment of asthma, allergy and inflammatory disorders
10/05/2000WO2000058292A1 Novel morpholine derivatives, method for the production thereof and pharmaceutical preparations containing said derivatives
10/05/2000WO2000057920A2 Method for expressing proteins
10/05/2000WO2000057912A1 Novel porcine protein and uses thereof
10/05/2000WO2000057911A2 Hapten-conjugated mammalian cells and methods of making and using thereof
10/05/2000WO2000057903A2 48 human secreted proteins
10/05/2000WO2000057896A1 Modulators of polysaccharides and uses thereof
10/05/2000WO2000057888A1 Compositions for preventing and treating type i allergy
10/05/2000WO2000057862A2 Use of gaba-b receptor ligands for the treatment of neurodegenerative diseases
10/05/2000WO2000057854A2 Mechanically stable pharmaceutical presentation form containing liquid or semi-solid surface-active substances
10/05/2000WO2000057727A1 Nutritional compositions which contain slightly negatively charged, non-digestible polysaccharides and the use thereof for reducing transport through tight junctions
10/05/2000WO2000057705A1 In vitro induction of antigen-specific t-cells using dendritic cell-tumor cell or dendritic cell-viral cell derived immunogens
10/05/2000WO2000031280A3 Use of plus-strand synthesis elements in retroviral vectors
10/05/2000WO2000029574A3 Inflammation-associated genes
1 ... 918 919 920 921 922 923 924 925 926 927 928 929 930 931 932 933 934 935 936 937 938 ... 1172